{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}],"title":"Patients with a Related, Grade 3 Toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"Patients with a Related, Grade 4 Toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Patients with a Related, Grade 5 Toxicity"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"To assess the safety of Cobimetinib treatment in CMML. This outcome measure will report the count of patients who experienced a Grade 3, Grade 4, and Grade 5 treatment-related adverse reaction while on study treatment.","groups":[{"description":"Patients treated with hypomethylating agent (HMA) refractory chronic myelomonocytic leukemia (CMML; 2022 WHO classification) with RAS pathway activation.\n\nExperimental: Treatment: All Patients Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.","id":"OG000","title":"HMA Refractory"},{"description":"Patients with newly diagnosed chronic myelomonocytic leukemia (CMML; 2022 WHO classification) with RAS pathway activation.\n\nExperimental: Treatment: All Patients Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.","id":"OG001","title":"Newly Diagnosed"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From the start of study treatment to the last dose of study treatment, up to 20 months","title":"Related Grade 3-5 Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}